{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:27:32Z","timestamp":1760189252496},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T00:00:00Z","timestamp":1328745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2474-13-15","type":"journal-article","created":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T12:16:21Z","timestamp":1328789781000},"source":"Crossref","is-referenced-by-count":24,"title":["African American patients with gout: efficacy and safety of febuxostat vs allopurinol"],"prefix":"10.1186","volume":"13","author":[{"given":"Alvin F","family":"Wells","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Chefo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,9]]},"reference":[{"key":"1350_CR1","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE: Epidemiology of gout: is the incidence rising?. J Rheumatol. 2002, 29: 2403-2406.","journal-title":"J Rheumatol"},{"key":"1350_CR2","first-page":"1582","volume":"31","author":"KL Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004, 31: 1582-1587.","journal-title":"J Rheumatol"},{"key":"1350_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.23176","volume":"58","author":"RC Lawrence","year":"2008","unstructured":"Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008, 58: 26-35. 10.1002\/art.23176.","journal-title":"Arthritis Rheum"},{"key":"1350_CR4","unstructured":"United States Census Bureau. Table 3. Annual Estimates of the Resident Population by Sex, Race, and Hispanic Origin for the United States: April 1, 2000 to July 1, 2009 (NC-EST2009-03). 2010, Available at: http:\/\/www.census.gov\/popest\/national\/asrh\/NC-EST2009-srh.html . Accessed February 14, 2011"},{"key":"1350_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.1780380508","volume":"38","author":"MC Hochberg","year":"1995","unstructured":"Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ: Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995, 38: 628-632. 10.1002\/art.1780380508.","journal-title":"Arthritis Rheum"},{"key":"1350_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","volume":"41","author":"RC Lawrence","year":"1998","unstructured":"Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998, 41: 778-799. 10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V.","journal-title":"Arthritis Rheum"},{"key":"1350_CR7","first-page":"498","volume":"35","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Lienesch D, Kwoh CK: Gout in ambulatory care settings in the United States. J Rheumatol. 2008, 35: 498-501.","journal-title":"J Rheumatol"},{"key":"1350_CR8","unstructured":"National Center for Health Statistics. Health, United States, 2009: With special feature on medical technology. 2010, Hyattsville, MD: Centers for Disease Control. U.S. Department of Health and Human Services"},{"key":"1350_CR9","first-page":"409","volume":"20","author":"B Batson","year":"2010","unstructured":"Batson B, Belletti D, Wogen J: Effect of African American race on hypertension management: a real-world observational study among 28 US physician practices. Ethn Dis. 2010, 20: 409-415.","journal-title":"Ethn Dis"},{"key":"1350_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM: Pathogenesis of gout. Ann Intern Med. 2005, 143: 499-516.","journal-title":"Ann Intern Med"},{"key":"1350_CR11","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMcp030733","volume":"349","author":"RA Terkeltaub","year":"2003","unstructured":"Terkeltaub RA: Clinical practice. Gout. N Engl J Med. 2003, 349: 1647-1655. 10.1056\/NEJMcp030733.","journal-title":"N Engl J Med"},{"key":"1350_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/BOR.0b013e3282f54d03","volume":"20","author":"MA Becker","year":"2008","unstructured":"Becker MA, Chohan S: We can make gout management more successful now. Curr Opin Rheumatol. 2008, 20: 167-172. 10.1097\/BOR.0b013e3282f54d03.","journal-title":"Curr Opin Rheumatol"},{"key":"1350_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004, 51: 321-325. 10.1002\/art.20405.","journal-title":"Arthritis Rheum"},{"key":"1350_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C: Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009, 36: 1273-1278. 10.3899\/jrheum.080814.","journal-title":"J Rheumatol"},{"key":"1350_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C: Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009, 48: 188-194.","journal-title":"Rheumatology (Oxford)"},{"key":"1350_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8","volume":"2","author":"EC Bartels","year":"1959","unstructured":"Bartels EC, Matossian GS: Gout: six-year follow-up on probenecid (benemid) therapy. Arthritis Rheum. 1959, 2: 193-202. 10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8.","journal-title":"Arthritis Rheum"},{"key":"1350_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006, 81: 925-934. 10.4065\/81.7.925.","journal-title":"Mayo Clin Proc"},{"key":"1350_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006, 65: 1312-1324. 10.1136\/ard.2006.055269.","journal-title":"Ann Rheum Dis"},{"key":"1350_CR19","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006, 33: 1646-1650.","journal-title":"J Rheumatol"},{"key":"1350_CR20","unstructured":"Uloric\u00ae Full Prescribing Information. 2011, Deerfield, IL: Takeda Pharmaceuticals North America, Inc."},{"key":"1350_CR21","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005, 353: 2450-2461. 10.1056\/NEJMoa050373.","journal-title":"N Engl J Med"},{"key":"1350_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008, 59: 1540-1548. 10.1002\/art.24209.","journal-title":"Arthritis Rheum"},{"key":"1350_CR23","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, Macdonald P, Lloyd E, Lademacher C: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010, 12: R63-10.1186\/ar2978.","journal-title":"Arthritis Res Ther"},{"key":"1350_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977, 20: 895-900. 10.1002\/art.1780200320.","journal-title":"Arthritis Rheum"},{"key":"1350_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159\/000180580.","journal-title":"Nephron"},{"key":"1350_CR26","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/00003246-199310000-00016","volume":"21","author":"S Robert","year":"1993","unstructured":"Robert S, Zarowitz BJ, Peterson EL, Dumler F: Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med. 1993, 21: 1487-1495. 10.1097\/00003246-199310000-00016.","journal-title":"Crit Care Med"},{"key":"1350_CR27","first-page":"1553","volume":"77","author":"DJ Belle","year":"2008","unstructured":"Belle DJ, Singh H: Genetic factors in drug metabolism. Am Fam Physician. 2008, 77: 1553-1560.","journal-title":"Am Fam Physician"},{"key":"1350_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/clpt.2009.223","volume":"87","author":"LH Cavallari","year":"2010","unstructured":"Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA: Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010, 87: 459-464. 10.1038\/clpt.2009.223.","journal-title":"Clin Pharmacol Ther"},{"key":"1350_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/jpet.103.054072","volume":"307","author":"L Villeneuve","year":"2003","unstructured":"Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C: Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 2003, 307: 117-128. 10.1124\/jpet.103.054072.","journal-title":"J Pharmacol Exp Ther"},{"key":"1350_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1124\/dmd.104.001800","volume":"33","author":"N Kaniwa","year":"2005","unstructured":"Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, Hasegawa R: Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American. Drug Metab Dispos. 2005, 33: 458-465.","journal-title":"Drug Metab Dispos"},{"key":"1350_CR31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/mol.60.2.382","volume":"60","author":"LJ Dickmann","year":"2001","unstructured":"Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001, 60: 382-387.","journal-title":"Mol Pharmacol"},{"key":"1350_CR32","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","volume":"372","author":"A Dehghan","year":"2008","unstructured":"Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, Benjamin EJ, van Duijn CM, Witteman JC, Coresh J, Fox CS: Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008, 372: 1953-1961. 10.1016\/S0140-6736(08)61343-4.","journal-title":"Lancet"},{"key":"1350_CR33","volume-title":"Rheumatology (Oxford)","author":"AD Rule","year":"2010","unstructured":"Rule AD, de Andrade M, Matsumoto M, Mosley TH, Kardia S, Turner ST: Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families. Rheumatology (Oxford). 2010"},{"key":"1350_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1755-8794-4-17","volume":"4","author":"BA Charles","year":"2011","unstructured":"Charles BA, Shriner D, Doumatey A, Chen G, Zhou J, Huang H, Herbert A, Gerry NP, Christman MF, Adeyemo A, Rotimi CN: A genome-wide association study of serum uric acid in African Americans. BMC Med Genomics. 2011, 4: 17-10.1186\/1755-8794-4-17.","journal-title":"BMC Med Genomics"},{"key":"1350_CR35","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/rheumatology\/keq037","volume":"49","author":"E Krishnan","year":"2010","unstructured":"Krishnan E: Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford). 2010, 49: 1229-1238. 10.1093\/rheumatology\/keq037.","journal-title":"Rheumatology (Oxford)"},{"key":"1350_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.107.129031","volume":"324","author":"MK Kutzing","year":"2008","unstructured":"Kutzing MK, Firestein BL: Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008, 324: 1-7.","journal-title":"J Pharmacol Exp Ther"},{"key":"1350_CR37","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E Krishnan","year":"2006","unstructured":"Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006, 54: 2688-2696. 10.1002\/art.22014.","journal-title":"Arthritis Rheum"},{"key":"1350_CR38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MJT.0b013e3181df8ad2","volume":"17","author":"A Whelton","year":"2010","unstructured":"Whelton A: Current and future therapeutic options for the management of gout. Am J Ther. 2010, 17: 402-417.","journal-title":"Am J Ther"},{"key":"1350_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2337\/dc07-1276","volume":"31","author":"A Dehghan","year":"2008","unstructured":"Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008, 31: 361-362.","journal-title":"Diabetes Care"},{"key":"1350_CR40","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2009.122770","volume":"69","author":"MA De Vera","year":"2010","unstructured":"De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK: Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010, 69: 1162-1164. 10.1136\/ard.2009.122770.","journal-title":"Ann Rheum Dis"},{"key":"1350_CR41","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G: Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007, 116: 894-900. 10.1161\/CIRCULATIONAHA.107.703389.","journal-title":"Circulation"},{"key":"1350_CR42","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","volume":"168","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH: Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008, 168: 1104-1110. 10.1001\/archinte.168.10.1104.","journal-title":"Arch Intern Med"},{"key":"1350_CR43","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1161\/01.HYP.0000249768.26560.66","volume":"48","author":"PB Mellen","year":"2006","unstructured":"Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, Wofford MR, Herrington DM: Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006, 48: 1037-1042. 10.1161\/01.HYP.0000249768.26560.66.","journal-title":"Hypertension"},{"key":"1350_CR44","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","volume":"283","author":"J Fang","year":"2000","unstructured":"Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. Jama. 2000, 283: 2404-2410. 10.1001\/jama.283.18.2404.","journal-title":"Jama"},{"key":"1350_CR45","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/art.22232","volume":"55","author":"F Perez-Ruiz","year":"2006","unstructured":"Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM: Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006, 55: 786-790. 10.1002\/art.22232.","journal-title":"Arthritis Rheum"},{"key":"1350_CR46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002, 47: 356-360. 10.1002\/art.10511.","journal-title":"Arthritis Rheum"},{"key":"1350_CR47","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23007","volume":"57","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Liote F: Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Rheum. 2007, 57: 1324-1328. 10.1002\/art.23007.","journal-title":"Arthritis Rheum"},{"key":"1350_CR48","doi-asserted-by":"publisher","first-page":"p69","DOI":"10.1159\/000127837","volume":"108","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, Zhao L, Johnson RJ: Effect of febuxostat on the progression of renal disease in 5\/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 2008, 108: p69-78. 10.1159\/000127837.","journal-title":"Nephron Physiol"},{"key":"1350_CR49","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","volume":"23","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ: Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008, 23: 1179-1185.","journal-title":"Nephrol Dial Transplant"},{"key":"1350_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L: Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011, 17: 7-13.","journal-title":"J Clin Rheumatol"},{"key":"1350_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/ard.41.1.59","volume":"41","author":"T Gibson","year":"1982","unstructured":"Gibson T, Rodgers V, Potter C, Simmonds HA: Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis. 1982, 41: 59-65. 10.1136\/ard.41.1.59.","journal-title":"Ann Rheum Dis"},{"key":"1350_CR52","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","volume":"39","author":"M Kanbay","year":"2007","unstructured":"Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007, 39: 1227-1233. 10.1007\/s11255-007-9253-3.","journal-title":"Int Urol Nephrol"},{"key":"1350_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006, 47: 51-59. 10.1053\/j.ajkd.2005.10.006.","journal-title":"Am J Kidney Dis"},{"key":"1350_CR54","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA: Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008, 67: 609-613.","journal-title":"Ann Rheum Dis"},{"key":"1350_CR55","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1002\/art.10480","volume":"46","author":"JM Jordan","year":"2002","unstructured":"Jordan JM, Lawrence R, Kington R, Fraser P, Karlson E, Lorig K, Liang MH: Ethnic health disparities in arthritis and musculoskeletal diseases: report of a scientific conference. Arthritis Rheum. 2002, 46: 2280-2286. 10.1002\/art.10480.","journal-title":"Arthritis Rheum"},{"key":"1350_CR56","unstructured":"2010 National Healthcare Disparities Report. Agency for Healthcare Research and Quality. 2011, AHRQ Publication No. 11-0005. [ http:\/\/www.ahrq.gov\/qual\/qrdr10.htm ]"},{"key":"1350_CR57","first-page":"330","volume":"19","author":"C Lee","year":"2009","unstructured":"Lee C, Ayers SL, Kronenfeld JJ: The association between perceived provider discrimination, healthcare utilization and health status in racial and ethnic minorities. Ethn Dis. 2009, 19: 330-337.","journal-title":"Ethn Dis"},{"key":"1350_CR58","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/art.24338","volume":"61","author":"F Constantinescu","year":"2009","unstructured":"Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L: Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum. 2009, 61: 413-418. 10.1002\/art.24338.","journal-title":"Arthritis Rheum"},{"key":"1350_CR59","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MLR.0b013e31818af829","volume":"47","author":"F Constantinescu","year":"2009","unstructured":"Constantinescu F, Goucher S, Weinstein A, Fraenkel L: Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009, 47: 350-355. 10.1097\/MLR.0b013e31818af829.","journal-title":"Med Care"},{"key":"1350_CR60","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/art.23243","volume":"59","author":"DC Ang","year":"2008","unstructured":"Ang DC, Monahan PO, Cronan TA: Understanding ethnic disparities in the use of total joint arthroplasty: application of the health belief model. Arthritis Rheum. 2008, 59: 102-108. 10.1002\/art.23243.","journal-title":"Arthritis Rheum"},{"key":"1350_CR61","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/15257770802136032","volume":"27","author":"MA Becker","year":"2008","unstructured":"Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N: Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008, 27: 585-591. 10.1080\/15257770802136032.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1350_CR62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cct.2006.10.001","volume":"28","author":"FT Shaya","year":"2007","unstructured":"Shaya FT, Gbarayor CM, Huiwen Keri Y, Agyeman-Duah M, Saunders E: A perspective on African American participation in clinical trials. Contemp Clin Trials. 2007, 28: 213-217. 10.1016\/j.cct.2006.10.001.","journal-title":"Contemp Clin Trials"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-15.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-13-15\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T09:21:33Z","timestamp":1640683293000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-13-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,9]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-13-15","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,9]]},"article-number":"15"}}